Acumen Hypotension Prediction Index EV1000 Clinical Platform vs AI-CVD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Acumen Hypotension Prediction Index EV1000 Clinical Platform

by Edwards Lifesciences

AI-CVD

by HeartLung Corporation

AI Verdict

Tool A is designed for real-time prediction and management of acute hypotensive events using continuous hemodynamic monitoring in critical care and surgical settings. Conversely, Tool B focuses on opportunistic screening for chronic cardiovascular and multisystem diseases by analyzing existing CT scans to identify hidden health risks. While both fall under Cardiology AI, they serve distinct clinical purposes and integrate into different workflows.

Choose Acumen Hypotension Prediction Index EV1000 Clinical Platform if…

Choose Acumen Hypotension Prediction Index if your clinical focus is on real-time, proactive management of acute hemodynamic instability during surgery or in critical care. This tool is ideal for anesthesiologists and critical care teams needing to predict and mitigate hypotensive events up to 15 minutes in advance, leveraging continuous hemodynamic monitoring and machine learning insights into preload, afterload, and contractility.

View Acumen Hypotension Prediction Index EV1000 Clinical Platform →

Choose AI-CVD if…

Choose AI-CVD if your primary goal is opportunistic screening for chronic cardiovascular and multisystem diseases using existing CT scans, without requiring additional imaging or workflow changes. This platform is best suited for radiologists and cardiologists looking to identify hidden health risks through automated analysis of CT-derived measurements like coronary artery calcium scores, cardiac chamber volumetry, and epicardial fat.

View AI-CVD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Acumen Hypotension Prediction Index EV1000 Clinical Platform	AI-CVD
Pricing	Contact-for-pricing	Contact for pricing
Deployment	Integrated with Edwards Lifesciences HemoSphere Advanced Monitoring Platform (and previously EV1000 Clinical Platform) via dedicated sensors (Acumen IQ cuff or sensor).	Cloud
FDA Status	1 AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Acumen Hypotension Prediction Index EV1000 Clinical Platform	AI-CVD
Name	Acumen Hypotension Prediction Index u2013 EV1000 Clinical Platform	AI-CVD
Company	Edwards Lifesciences	HeartLung Corporation
Tagline	Predicting and managing hypotension before it occurs.	Advancing AI-enabled, CT-based opportunistic screening and early disease detection.
Primary Function	Predicts hypotensive events up to 15 minutes in advance using machine learning.	Performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans.
Categories	Cardiology AI, Surgical AI, Triage & ER/ICU AI	Cardiology AI
Specialties	Anesthesiology, Critical Care, Emergency Medicine	Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index EV1000 Clinical Platform and AI-CVD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How does each tool integrate into existing clinical workflows for patient care?

Acumen HPI integrates directly with Edwards Lifesciences HemoSphere Advanced Monitoring Platform via dedicated sensors for continuous, real-time hemodynamic monitoring in acute care settings. AI-CVD performs opportunistic screening using existing CT scans, requiring no additional imaging, radiation, contrast, or disruption to the current imaging workflow.

For which specific clinical scenarios or patient populations is each tool most effective?

Acumen HPI is designed for anesthesiology, critical care, and emergency medicine to predict and manage intraoperative hypotension and hemodynamic instability. AI-CVD is suited for cardiology, pulmonology, and radiology to enable early detection of hidden cardiovascular and multisystem disease risks through opportunistic screening from existing CT scans.

What is the typical process for integrating the output of each tool into a patient's electronic health record?

Acumen HPI integrates with the Edwards Lifesciences HemoSphere platform, suggesting data would flow from this monitoring system into the EHR. AI-CVD generates automated CT-derived measurements and analyses from existing scans, which would then need a mechanism to be incorporated into the EHR.

What data supports the accuracy and sensitivity of each tool's predictions or detections?

Acumen HPI utilizes a machine learning-based algorithm to predict hypotensive events up to 15 minutes in advance, providing a 0-100 likelihood score. AI-CVD is an FDA-cleared quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans.

What is the expected learning curve for clinicians to effectively utilize each tool, and how quickly can a practice expect to see clinical value?

Acumen HPI involves understanding parameters like the HPI score, Smart Alerts, and Relationship View within a continuous monitoring environment, which requires training on the integrated platform. AI-CVD provides automated measurements from existing scans, suggesting the learning curve focuses on interpreting the quantitative results for early disease detection and integrating them into clinical decision-making.

What is the fundamental difference in the clinical problem each tool aims to solve for a physician?

Acumen HPI addresses the immediate and acute challenge of predicting and proactively managing hemodynamic instability and hypotension in real-time during critical care. AI-CVD focuses on the long-term preventative health challenge of opportunistically screening for hidden cardiovascular and multisystem diseases using existing imaging to enable early detection.